ClinicalTrials.gg
RecruitingNCT07857200RISKUpdated Nov 16, 2026

The Use of Risk Prediction to Identify Patients at Risk for Chronic Kidney Disease: Patient and Provider Interventions for Patients at High Risk for Chronic Kidney Disease

An interventional study of Letter Intervention and Letter + Phone Call Intervention: in CKD - Chronic Kidney Disease, sponsored by Kaiser Permanente. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Kaiser Permanente · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Nov 16, 2026Primary outcomes revisedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,500
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 988 studies in Renal Insufficiency, Chronic with a site in United States — 168 open to participants now, 215 under way, 25 of them phase 3. Renal Insufficiency, Chronic · United States.

Planned enrollment
46th of 819
1,500 · median 72
Started
2026
with 43 others
No phase
314 of 988
62 open now
Primary completion
2027-08
later than 102 of 213 live
Registered
979th of 988
by date

Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, this one is the 46th largest by planned enrollment of the 819 interventional ones that give a count, is one of 44 that started in 2026, is one of 314 with no phase, reaches primary completion later than 102 of the 213 other live ones, and was the 979th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

168 of the 988 studies in Renal Insufficiency, Chronic with a site in United States are open now. Recruiting first, the newest first:

162 more — sign in →

All 168 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 988 studies in Renal Insufficiency, Chronic with a site in United States, or all of them as a file.
02

Study summary

This prospective, cluster-randomized trial is structured as a pragmatic study, embedding the outreach intervention within routine clinical workflows. The intervention reflects real-world provider-patient communication methods. The primary research aim is to evaluate, under typical practice conditions, whether structured notification strategies improve follow-up screening.

We will evaluate whether targeted provider and patient-directed communication increases completion of CKD disease lab testing (eGFR and uACR) among individuals identified as being at risk for having CKD based on the model developed in in Phase 1. We will identify up to 1,000 patients with high risk of having CKD. All patients' primary care providers (PCPs) will receive a message notifying them of patients' elevated risk status and the recommendation for CKD testing per standard practice. Additionally, we will randomly allocate providers whose patients will receive letters ( \~n=500 patients) and providers whose patients will receive a phone call ( \~n=250 patients).

03

Conditions studied

  • CKD - Chronic Kidney Disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At high risk for CKD as determined by CKD model developed in Phase 1
  • Age 18-80 as of date of data pull
  • At least 12 months of health plan coverage
  • Speaks English or Spanish
  • We will include both paneled and unpaneled patients

Exclusion criteria

Exclusion criteria:

  • On the research exclusion list between 1/1/2013 and date of the data pull
  • On hospice, or have conditions that indicate end of life ( cancer, on dialysis, etc.)
  • Non-English / non-Spanish speaking (those who are excluded from the intervention arm solely due to language barriers will be reported to the IRB at continuing review).
  • Pregnant patients.
  • Patients who have a completed both the and uACR within the 12 months prior to the date of cohort identification.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,500 participants (estimated)

Study arms

  • Other
    Augmented Usual Care

    All PCPs (\~n=280) of 1,000 eligible patients will receive a secure message, developed by the research team and delivered by a research team member with EHR access. The message will notify the PCP of the patients' elevated risk of developing CKD and need for standard CKD testing and provide a smart-set to order eGFR or UACR tests.

    Other: Augmented usual care

  • Other
    Letter Intervention

    An estimated 140 PCPs will be randomized, for their patients (\~\<500 patients) to receive the letter via mail, developed by the research team and delivered by USPS. Letters will be sent to each patient notifying them of their elevated risk of developing CKD and information regarding standard CKD testing.

    Other: Letter Intervention · Other: Augmented usual care

  • Other
    Letter + Phone Call Intervention

    Approximately 70 providers will be randomized for their patients (\~n\<250) to receive the phone intervention notifying them of their elevated risk and recommending CKD testing.

    Other: Letter Intervention · Other: Letter + Phone Call Intervention: · Other: Augmented usual care

Interventions

  • OtherLetter Intervention

    An estimated 140 PCPs will be randomized, for their patients (\~\<500 patients) to receive the letter via mail, developed by the research team and delivered by USPS. Letters will be

  • OtherLetter + Phone Call Intervention:

    Additionally, approximately 70 providers will be randomized for their patients (\~n\<250) to receive the phone intervention notifying them of their elevated risk and recommending CKD testing.

  • OtherAugmented usual care

    All PCPs (\~n=280) of 1,000 eligible patients will receive a secure message, developed by the research team and delivered by a research team member with EHR access. The message will notify the PCP of the patients' elevated risk of developing CKD and need for standard CKD testing and provide a smart-set to order eGFR or UACR tests.

06

What researchers measure

Primary outcomes

  1. Number of days from index date (date of first provider notification) to the screening completion date by either eGFR(creatinine) or UACR, whichever comes earlier, during the follow-up period. The primary outcome will be assessed up to 12 months.

    We will group populations based on risk score, demographics (including historically underserved groups such as Medicaid beneficiaries and individuals of diverse race/ethnicity), comorbidities, and the presence and recency of urine albumin-to-creatinine ratio (uACR) and estimated Glomerular Filtration Rate (eGFR) testing to identify those at high risk for CKD. All patients will have a message sent to the provider to complete steps to screen for CKD per CDC and KPNW clinical guidelines. A randomized portion of providers will have letters sent to their patients with elevated risk, and an additional portion will receive a phone call recommending CKD lab tests.

    Time frame: Up to 12 months

Secondary outcomes

  1. Time to CKD diagnosis

    The time from index date to CKD diagnosis will be assessed using electronic health record (EHR) data.

    Time frame: Up to 12 months

07

Study locations

1 of 1 sites recruiting
  • Center for Health Research, Kaiser Permanente NW
    Portland, Oregon 97227, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — A de-identified analytic dataset may be available upon request.

Supporting information: Study protocol, Statistical analysis plan

Time frame: After completion of the study and for up to 5 years thereafter.

Access criteria: Written requests submitted to the study PI with a scientific justification

Data sharing details ↗ · research.kpchr.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Aug 2027, 12 months after the start.

Of 580 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 12 months is below that.

Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2026
First posted
Oct 5, 2026
StartActual
Aug 20, 2026
Primary completionEst.
Aug 20, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionNumber of days from index date (date of first provider notification) to the screening completion date by either eGFR(creatinine) or UACR, whichever comes earlier, during the follow-up period. The primary outcome will be assessed up to 12 months.: how it is measured was reworded
Nov 16, 2026
Registered
First appeared on the registry
Oct 5, 2026
Show all 2 updates
  1. Nov 16, 2026
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionNumber of days from index date (date of first provider notification) to the screening completion date by either eGFR(creatinine) or UACR, whichever comes earlier, during the follow-up period. The primary outcome will be assessed up to 12 months.: how it is measured was reworded
    + 1 other change: arm descriptions
  2. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07857200
Lead sponsor
Kaiser Permanente
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Aug 20, 2026
Primary completion
Aug 20, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Amanda F Pretrik, PhD
Contact
Amanda.F.Petrik@kpchr.org
503-335-2400

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion